Patriot Investment Management Inc. Has $2.14 Million Position in Johnson & Johnson (NYSE:JNJ)
Patriot Investment Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 0.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,308 shares of the company’s stock after buying an additional 140 shares during the quarter. Patriot Investment Management Inc.’s holdings in Johnson & Johnson were worth $2,138,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 38,393,079 shares of the company’s stock valued at $5,589,167,000 after buying an additional 1,364,028 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Johnson & Johnson by 3.2% in the fourth quarter. Bank of New York Mellon Corp now owns 32,846,195 shares of the company’s stock valued at $4,791,274,000 after buying an additional 1,021,877 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $4,139,107,000. Massachusetts Financial Services Co. MA increased its stake in shares of Johnson & Johnson by 3.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 27,407,188 shares of the company’s stock valued at $3,997,886,000 after buying an additional 915,066 shares in the last quarter. Finally, FMR LLC increased its stake in shares of Johnson & Johnson by 4.7% in the fourth quarter. FMR LLC now owns 17,945,766 shares of the company’s stock valued at $2,617,750,000 after buying an additional 799,194 shares in the last quarter. Institutional investors own 67.66% of the company’s stock.
In other Johnson & Johnson news, Director William D. Perez acquired 500 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The business had revenue of $20.69 billion for the quarter, compared to analysts’ expectations of $19.48 billion. During the same quarter in the previous year, the business posted $2.10 EPS. Johnson & Johnson’s revenue for the quarter was up 3.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 7.68 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.80%. The ex-dividend date of this dividend is Friday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s payout ratio is 43.78%.
Several equities analysts recently issued reports on JNJ shares. UBS Group cut Johnson & Johnson from a “buy” rating to a “neutral” rating and decreased their price target for the company from $163.00 to $160.00 in a report on Tuesday, April 28th. Raymond James raised their price target on Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Barclays raised their price target on Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Argus reiterated a “buy” rating and issued a $155.00 price target (down previously from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. Finally, SVB Leerink decreased their price target on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $163.47.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: How is the S&P 500 index different from the DJIA?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.